During Friday's "Lightning Round" segment of Mad Money, one caller quizzed Jim Cramer about NantKwest (NK) . "I'm going to say yes to this speculative company. I'm fine with it," said Cramer about this a clinical-stage immunotherapy company.
More from Investing
If I'm bearish or short, I am getting very, very nervous about Tuesday's action.
It appears we could be looking at a setup for a failed bounce or the start of a fresh leg higher.
Let's make sense of investing in non-fungible tokens as they meet exchange-traded funds with the recent launch of the Defiance Digital Revolution fund.
It is quite ironic that the one asset that was truly meant to be a diversification tool, ended up being just the same as the rest.